scholarly journals CD45RC Expression of Circulating CD8+ T Cells Predicts Acute Allograft Rejection: A Cohort Study of 128 Kidney Transplant Patients

2019 ◽  
Vol 8 (8) ◽  
pp. 1147 ◽  
Author(s):  
Lemerle ◽  
Garnier ◽  
Planchais ◽  
Brilland ◽  
Subra ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Kidney Transplant ◽  
Cd8 T Cells ◽  
De Novo ◽  
Predictive Biomarkers ◽  
Transplant Patients ◽  
History Of ◽  
Kidney Transplant Patients ◽  
A Prospective Study

Predictive biomarkers of acute rejection (AR) are lacking. Pre-transplant expression of CD45RC on blood CD8+ T cells has been shown to predict AR in kidney transplant (KT) patients. The objective of the present study was to study CD45RC expression in a large cohort of KT recipients exposed to modern immunosuppressive regimens. CD45RC expression on T cells was analyzed in 128 KT patients, where 31 patients developed AR, of which 24 were found to be T-cell mediated (TCMR). Pre-transplant CD4+ and CD8+ CR45RChigh T cell proportions were significantly higher in patients with AR. The frequency of CD45RChigh T cells was significantly associated with age at transplantation but was not significantly different according to gender, history of transplantation, pre-transplant immunization, and de novo donor specific anti-Human Leucocyte Antigen (HLA) antibody. Survival-free AR was significantly better in patients with CD8+ CD45RChigh T cells below 58.4% (p = 0.0005), but not different according to CD4+ T cells (p = 0.073). According to multivariate analysis, CD8+ CD45RChigh T cells above 58.4% increased the risk of AR 4-fold (HR 3.96, p = 0.003). Thus, pre-transplant CD45RC expression on CD8+ T cells predicted AR, mainly TCMR, in KT patients under modern immunosuppressive therapies. We suggest that CD45RC expression should be evaluated in a prospective study to validate its usefulness to quantify the pre-transplant risk of AR.

scholarly journals Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Fleur S. Peters ◽  
Annemiek M. A. Peeters ◽  
Pooja R. Mandaviya ◽  
Joyce B. J. van Meurs ◽  
Leo J. Hofland ◽  
...  
Keyword(s):  
At Risk ◽  
T Cells ◽  
Skin Cancer ◽  
Kidney Transplant ◽  
De Novo ◽  
Differentially Methylated Regions ◽  
Transplant Patients ◽  
Patients At Risk ◽  
Kidney Transplant Patients

scholarly journals Differentially Methylated Regions in T Cells Identify Kidney Transplant Patients at Risk for De Novo Skin Cancer

2018 ◽  
Vol 102 ◽  
pp. S183
Author(s):  
Fleur S Peters ◽  
Annemiek M Peeters ◽  
Pooja R Mandaviya ◽  
Joyce B van Meurs ◽  
Leo J Hofland ◽  
...  
Keyword(s):  
At Risk ◽  
T Cells ◽  
Skin Cancer ◽  
Kidney Transplant ◽  
De Novo ◽  
Differentially Methylated Regions ◽  
Transplant Patients ◽  
Patients At Risk ◽  
Kidney Transplant Patients

scholarly journals Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines

2021 ◽  
Author(s):  
Maria Prendecki ◽  
Tina Thomson ◽  
Candice L Clarke ◽  
Paul Martin ◽  
Sarah Gleeson ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
T Cell Responses ◽  
Cellular Responses ◽  
Control Group ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cell Responses ◽  
Transplant Patients ◽  
Kidney Transplant Patients

Background Attenuated immune responses to mRNA SARS-CoV-2 vaccines have been reported in solid organ transplant recipients. Most studies have assessed serological responses alone, and there is limited immunological data on vector-based vaccines in this population. This study compares the immunogenicity of BNT162b2 with ChAdOx1 in kidney transplant patients, assessing both serological and cellular responses. Methods 920 patients were screened for spike protein antibodies (anti-S) following 2 doses of either BNT162b2 (n=490) or ChAdOx1 (n=430). 106 patients underwent assessment with T-cell ELISpot assays. 65 health care workers were used as a control group. Results Anti-S was detected in 569 (61.8%) patients. Seroconversion rates in infection-naïve patients who received BNT162b2 were higher compared with ChAdOx1, at 269/410 (65.6%) and 156/358 (43.6%) respectively, p<0.0001. Anti-S concentrations were higher following BNT162b, 58(7.1-722) BAU/ml, compared with ChAdOx1, 7.1(7.1-39) BAU/ml, p<0.0001. Calcineurin inhibitor monotherapy, vaccination occurring >1st year post-transplant and receiving BNT162b2 was associated with seroconversion. Only 28/106 (26.4%) of patients had detectable T-cell responses. There was no difference in detection between infection-naïve patients who received BNT162b2, 7/40 (17.5%), versus ChAdOx1, 2/39 (5.1%), p=0.15. There was also no difference in patients with prior infection who received BNT162b2, 8/11 (72.7%), compared with ChAdOx1, 11/16 (68.8%), p=0.83. Conclusions. Enhanced humoral responses were seen with BNT162b2 compared with ChAdOx1 in kidney transplant patients. T-cell responses to both vaccines were markedly attenuated. Clinical efficacy data is still required but immunogenicity data suggests weakened responses to both vaccines in transplant patients, with ChAdOx1 less immunogenic compared with BNT162b2.

Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies

2001 ◽  
Vol 27 (6) ◽  
pp. 987-991 ◽  
Author(s):  
R. Sabat ◽  
C. Höflich ◽  
W.D. Döcke ◽  
F. Kern ◽  
H.-D. Volk ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Plasma Levels ◽  
Transplant Patients ◽  
Kidney Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document